Alison Davis

机构：Australian National University, Canberra Hospital · ORCID：0000-0003-4425-7871

发表论文 127 篇 · 总被引 3431 次 · h-index 31

代表论文

• Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup (2022 · The Lancet Oncology · 被引 144)
• GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee (2022 · Cancer Treatment Reviews · 被引 36)
• Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study (2022 · International Journal of Gynecological Cancer · 被引 33)
• An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva (2024 · Science Translational Medicine · 被引 21)
• Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study). (2023 · Journal of Clinical Oncology · 被引 21)
• Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023 · Genome Medicine · 被引 15)